Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Johns Hopkins Bloomberg School of Public Health International Centre for Diarrhoeal Disease Research, Bangladesh United States Agency for International Development (USAID) Agency for Healthcare Research and Quality (AHRQ) |
---|---|
Information provided by: | Johns Hopkins Bloomberg School of Public Health |
ClinicalTrials.gov Identifier: | NCT00470158 |
With the long-term public health goal of developing an effective micronutrient supplementation program to improve child health by improving iron and zinc status and decreasing morbidity due to diarrhea in areas with high rates of childhood malnutrition, we seek to determine the most efficacious method of decreasing childhood morbidity and mortality due to diarrhea in toddlers by re-examining the issue of iron and zinc interaction and determining if this interaction can be minimized by separate administration of iron and zinc supplementation.
Condition | Intervention | Phase |
---|---|---|
Anemia Diarrhea Iron |
Drug: iron alternating daily with placebo Drug: zinc alternating daily with placebo Drug: iron and zinc combined alternating daily with placebo Drug: iron alternating daily with zinc Drug: placebo daily |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | Delivery of Iron and Zinc Supplements: Evaluation of Interaction Effect on Biochemical and Clinical Outcomes |
Estimated Enrollment: | 1000 |
Study Start Date: | May 2007 |
Estimated Study Completion Date: | June 2008 |
Iron supplementation is used in reducing anemia and improving hemoglobin status. Zinc supplementation is emerging as possibly an efficacious preventive measure in decreasing incidence of severe diarrhea. Previous studies have suggested interactions of zinc and iron when given together, reducing the effects of supplementation with both minerals. One study in Peru has shown a decrease in interaction effect with separate supplementation of iron and zinc in time when compared to iron administration alone or placebo; however, an evaluation of clinical outcomes and zinc or iron status when iron and zinc are administered separately compared to supplementation of zinc and iron together or each alone has not previously been done. This trial will assess the effect of iron and zinc supplementation given on alternate days compared with giving them together in a combined supplement.
We propose a randomized, double blind, placebo-controlled community trial of children 6-23 months in Mirzapur, Bangladesh. We will recruit and enroll 1000 children 6-23 months old who are permanent residents of the selected villages. Each child will be randomly assigned to 1) daily alternating zinc and placebo 2) daily alternating iron/folic acid and placebo 3) daily alternating zinc/iron/folic acid and placebo 4) daily alternating zinc and iron/folic acid 5) daily placebo. Primary outcomes will include incidence of severe diarrhea, evaluated weekly for 6 months, hemoglobin, prevalence of anemia, and serum zinc.
Analysis of the data will be done to compare the effect of separate iron and zinc supplementation as compared to combined iron and zinc supplementation as well as compared to iron, zinc, or placebo single supplementation. We will evaluate the difference in incidence rate of severe diarrhea, serum hemoglobin, percent anemia, and serum zinc. Since this will be a randomized, double-blind, placebo controlled trial, differences in effect will be most likely explained by the timing of supplement doses. If there is an improvement in clinical and biochemical outcomes, this would be consistent with a decreased interaction of absorption. If no difference is found, there may be another mechanism for the seeming interaction of iron and zinc besides that of mutually inhibitory absorption in the intestine.
Ages Eligible for Study: | 6 Months to 18 Months |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contact: Shams El Arifeen, MBBS, PhD | +880-2-881 0115 | shams@icddrb.org |
Contact: Marge Koblinsky, MD, MPH | +(8802) 988 5155 | margek@icddrb.org |
Bangladesh, Mohakhali | |
ICDDR,B | Recruiting |
Dhaka, Mohakhali, Bangladesh, 1212 | |
Contact: Shams El Arifeen, MBBS, PhD +880-2-881 0115 shams@icddrb.org |
Principal Investigator: | Robert E Black, MD, MPH | Johns Hopkins Bloomberg School of Public Health |
Study ID Numbers: | H.22.05.03.11.C2, GHS-A-00-03-00019-00-90027844 |
Study First Received: | May 3, 2007 |
Last Updated: | May 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00470158 History of Changes |
Health Authority: | United States: Institutional Review Board; Bangladesh: Ethical Review Committee |
zinc iron interaction diarrhea delivery |
Signs and Symptoms Diarrhea Signs and Symptoms, Digestive Zinc |
Anemia Trace Elements Micronutrients Iron |
Signs and Symptoms Diarrhea Signs and Symptoms, Digestive Growth Substances Physiological Effects of Drugs |
Zinc Trace Elements Micronutrients Iron Pharmacologic Actions |